PCI Begins Move-In Phase of European Clinical Site Expansion

PCI Clinical Services (PCI) has begun to move into its expanded Clinical Services Center of Excellence at Bridgend, UK.

The new storage and distribution facility will provide PCI with a substantial addition of space, complementing its existing footprint currently utilized for specialist clinical trial logistics as well as packaging, labeling and qualified person activities for investigational medicinal products.

Full completion is scheduled for September 2017, with the facility set to be validated and operational by January 2018.

The latest addition to PCI’s Clinical Services Center of Excellence provides a modern, high-spec unit with warehouse and office space across two floors, purpose-built to support PCI’s specialist secondary packaging, storage and logistical needs. It also provides scope for further expansion in the future with an option for a further addition to the new building – reinforcing PCI’s strategy for continued growth and its ongoing commitment to investing in its Clinical Services provision.

Once operational, the new facility will give PCI the opportunity to offer its capability and expertise in supporting temperature-sensitive therapies, including cold chain and ultra cold chain, at temperatures ranging from controlled ambient 15-25°C, 2-8°C, down to -20°C, -30°C -40°C, -60°C to -90°C and including liquid nitrogen vapor phase storage below -150°C for advanced therapeutic medicinal products (ATMPs), as well as bespoke refrigerated and frozen temperatures according to client needs.
 
"We are seeing growing global demand for temperature-controlled packaging and labeling services for many therapeutic categories and drug delivery forms, particularly for growth in biologics as well as the exciting advances in cell and gene therapy," said Fiona Withey, managing director, UK Clinical Services, PCI. "Our latest investment at Bridgend allows us to continue to provide extensive resources and capacity to meet the changing needs of our clients, providing extra, highly specialized infrastructure for their products and ensuring a safe, secure supply chain to expedite the development of their life-saving medicines for patients around the world."